

CLAIMS

1. Use of Durvalumab or an antigen binding fragment thereof in the manufacture of a medicament for the treatment of a bladder cancer in a subject in need thereof, wherein the durvalumab or the antigen binding fragment thereof is to be administered to the subject in an amount to provide 20 mg/kg Q4W durvalumab or an antigen binding fragment thereof to treat the bladder cancer.
2. The use of claim 1, wherein the subject's bladder cancer is urothelial carcinoma (UC), advanced UC, or metastatic UC.
3. The use of claim 2, wherein the subject's UC is identified as PD-L1-low or PD-L1-low/neg for PD-L1 expression.
4. The use of claim 2, wherein the subject's UC is identified as PD-L1-high for PD-L1 expression.
5. The use of claim 1 or claim 2, wherein the subject has previously undergone a first line cancer therapy comprising a platinum drug or a platinum drug in combination with another anti-cancer agent.
6. The use of claim 5, wherein the first line cancer therapy comprises a therapy selected from cisplatin,
cisplatin and gemcitabine,
cisplatin, ~~and~~ methotrexate, vinblastine, and ADRIAMYCIN™ (doxorubicin), or
carboplatin and gemcitabine doublet combination.
7. The use of claim 1, wherein the bladder cancer is ~~urothelial~~ urothelial carcinoma (UC) and/or cancer of bladder-associated structures and tissue comprising ureter, urethra, urachus and/or renal pelvis.